{
    "questions": [
        {

            "text": "Based on the report what type of cancer has the patient got?",
            "type": "both[done]"
        },

      {
        "text": "Is pancreatic adenocarcinoma an aggressive disease?",
        "type": "both"
      },
      {
        "text": "What is the rate of survival for pancreatic cancer?",
        "type": "both"
      },
      {
        "text": "What is the typical treatment option for pancreatic cancer?",
        "type": "both"
      },
      {
        "text": "Is there targeted therapy for pancreatic cancer?",
        "type": "both"
      },
      {
        "text": "Is there immunotherapy available for pancreatic cancer?",
        "type": "both"
      },
      {
        "text": "Are there side-effects of immunotherapy for pancreatic cancer patients?",
        "type": "both"
      },
      {
        "text": "Are mutations in TP53, FBXW7, APC common in colon cancer?",
        "type": "both"
      },
      {
        "text": "Are CDK6 amplification and EGFR amplification common in colon cancer?",
        "type": "both"
      },
      {
        "text": "Do TP53, FBXW7, APC mutations make colon cancer aggressive?",
        "type": "both"
      },
      {
        "text": "What is the typical treatment option for colon cancer?",
        "type": "both"
      },
      {
        "text": "Is there targeted therapy for CDK6 amplification and EGFR amplification for colon cancer?",
        "type": "both"
      },
      {
        "text": "What does MSI-H indicate for colon cancer?",
        "type": "both"
      },
      {
        "text": "Do MSI-H colon cancer cases have poor outcomes?",
        "type": "both"
      }
    ]
  }
  